Q-omics provides the consensus-scored RPL5P35 profile across patient tissues and cancer cell-line models. RPL5P35 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPL5P35 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, RPL5P35 RNA expression shows 6,168 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight OV, BRCA, and STAD as cancer lineages where RPL5P35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL5P35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL5P35 survival associations across molecular data types. RPL5P35 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL5P35 RNA expression–survival associations across cancer types. High RPL5P35 expression shows unfavorable associations in OV and STAD, but favorable associations in THCA, LAML, MESO and ESCA. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for RPL5P35 RNA expression.
This table summarizes RPL5P35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL5P35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL5P35 shows lower tumor expression in BRCA and UCEC and higher tumor expression in LUAD, LIHC and PAAD. The BRCA box plot shows higher RPL5P35 RNA expression in normal versus tumor tissue (log2 FC = −0.058, t-test p = .003).
This table shows molecular features associated with RPL5P35 in patient tissues and cancer cell lines. In patient samples, RPL5P35 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
